Rapid COVID-19 Diagnostic Platform Using Saliva
ni2o, inc., Providence, Rhode Island, United States
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: Automated point-of-care and at-home multiplex test detecting IgA, IgM, and IgG antibodies toward SARS-CoV-2 in saliva, in 5 minutes. The portable device displays quantitative results and can connect to external applications. It will be extended with additional assays, functioning as a platform for viral detection for COVID and other pathogens.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: Ni2o’s RapidTest technology allows complex immunoassays to be performed outside of a biochemistry lab, testing for a variety of conditions without the need for specialized equipment or training. Ni2o RapidTest can detect early, ongoing, or late-stage infection of SARS-CoV-2, even if the user has no symptoms. Insight into individual differences in immune responses to the virus will facilitate vaccine and treatment development. In the future, as cartridges for other pathogens are developed, anyone with the device can have the capability to test for a variety of conditions simply by ordering the cartridges, collecting the sample, and loading them into the machine. This versatile design offers potential partners a platform for automated immunoassay analysis which can be vastly expanded and utilized in locations with limited access to traditional medical testing, providing an entryway to previously untouched markets due to its affordability and ease of use. A low cost system for automation of the ELISA process will increase the accessibility, accuracy, and understanding of epidemiology throughout the world. Patients without insurance or access to lab-quality testing will be able to afford diagnostics, and many may choose to use RapidTest instead of traditional methods in the interest of cost and speed.